Sickle cell anemia
Drug research and approvals for sickle cell anemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 162 studies of sickle cell anemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 4 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 162
- Trials authorized in Canada: 7
- FDA orphan approvals: 4
- EU medicines: 0
- Hemoglobin Disorders in Egypt: Sickle Cell Disease Ain Shams University Institutional RegistryNCT07800247 · Not reported · Ain Shams University · starts Mar 17, 2024
- Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical TomographyNCT07776444 · Not applicable · Washington University School of Medicine · starts Oct 1, 2025
- Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health SystemNCT07753681 · Not reported · Centre for Infectious Disease Research in Zambia · starts Aug 8, 2022
- Universal Newborn Screening For Sickle Cell Disease In MozambiqueNCT07719972 · Not applicable · St. Jude Children's Research Hospital · starts Sep 24, 2026
- Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell DiseaseNCT07708350 · Phase 1 · Daniel Bauer · starts Aug 1, 2026
- Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum…NCT07708714 · Phase 1 / Phase 2 · Children's Hospital Medical Center, Cincinnati · starts May 13, 2026
- Virtual Reality for SCD VOCNCT07674277 · Not applicable · University of Maryland, Baltimore · starts Nov 1, 2026
- A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)NCT07656415 · Phase 3 · Agios Pharmaceuticals, Inc. · starts Jul 21, 2026
- Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseNCT07616154 · Phase 2 · St. Jude Children's Research Hospital · starts Sep 10, 2026
Approved 7
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- VoxelotorHemoglobin HbA positive modulator
- CrizanlizumabP-selectin blocker
- Glutamine
- Deferiprone
- Lovotibeglogene autotemcelHemoglobin beta chain exogenous gene
- Exagamglogene autotemcelB-cell lymphoma/leukemia 11A gene editing negative modulator
Phase 3 12 of 19
- AlemtuzumabCAMPATH-1 antigen inhibitor
- Fludarabine
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
- PrasugrelPurinergic receptor P2Y12 antagonist
- DeferasiroxIron chelating agent
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- SenicapocIntermediate conductance calcium-activated potassium channel protein 4 blocker
- AcetylcysteineGlutathione precursor
- OxygenEssential for cellular homeostasis
- Vepoloxamer
- HydromorphoneMu opioid receptor agonist
- MethylphenidateDopamine transporter inhibitor
Phase 2 12 of 70
- SirolimusFK506-binding protein 1A inhibitor
- CyclophosphamideDNA inhibitor
- PlerixaforC-X-C chemokine receptor type 4 partial agonist
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- BusulfanDNA inhibitor
- EtavopivatPyruvate kinase isozymes R/L activator
- Osivelotor
- Nitrous acid
- TovinontrinePhosphodiesterase 9A inhibitor
- TilarginineNitric oxide synthase inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- ThiotepaDNA inhibitor
Phase 1 or earlier 12 of 44
- L-citrulline
- CyclosporineCyclophilin A modulator
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- Pociredir
- AmbrisentanEndothelin receptor, ET-A/ET-B antagonist
- BupropionDopamine transporter inhibitor
- CodeineOpioid receptors; mu/kappa/delta agonist
- FlurbiprofenCyclooxygenase inhibitor
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- PanobinostatHistone deacetylase inhibitor
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
How its trials ended
1,021 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 247 whose ending is known, 28% met their primary endpoint, 9% missed it and 63% stopped early.
- Completed, result not reported42842%
- Ongoing27927%
- Stopped: other or unclear737%
- Met its primary endpoint697%
- Status unknown677%
- Stopped: enrollment or feasibility465%
- Missed its primary endpoint222%
- Stopped: sponsor or business decision151%
- Stopped: lack of efficacy121%
- Stopped: funding91%
- Stopped: safety1<1%
| Dec 9, 2025 | A phase 2/3 randomized, multicenter study of osivelotor administered orally to adult and adolescent participants with sickle cell diseaseOsivelotor (PF-07940367, GBT021601) | Pfizer | Pending |
| May 22, 2024 | Optima study : optimizing hydroxyurea dosage with pharmakokinetic in patients suffering of moderate to severe sickle cell anemia.Hydroxyurea | Dr. Yves Pastore | Ongoing |
| Jun 4, 2018 | A vitamin D intervention in children with sickle cell disease: a pilot randomised controlled trialVitamin D | Chu Sainte Justine | Ongoing |
| Apr 20, 2018 | A randomised, double-blind, parallel-group, multicentre, phase III study to evaluate the effect of ticagrelor versus placebo in reducing the rate of…Brilinta (ticagrelor) | AstraZeneca Pharmaceuticals | Closed |
| Nov 25, 2016 | A multiple-dose, subject-and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885…ACZ885 (canakinumab) | Novartis Pharmaceuticals | Closed |
| Apr 24, 2013 | A phase 3, double-blind, randomized, efficacy and safety comparison of prasugrel and placebo in pediatric patients with sickle cell diseasePrasugrel (LY640315) | Eli Lilly | Ongoing |
| Apr 2, 2013 | The pharmacokinetic profile of a single dose of ferriprox® in patients with sickle cell diseaseDeferiprone | Apopharma Inc | Closed |
| Dec 23, 2024 | XromiTo reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients 6 months of age and older with… | Nova Laboratories Limited | Approved |
| Apr 4, 2024 | XromiTo reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age to less… | Nova Laboratories Limited | Approved |
| Dec 21, 2017 | SiklosTo reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older,… | Theravia Pharma | Approved |
| Feb 25, 1998 | DroxiaTo reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with… | Bristol-Myers Squibb Pharmaceutical Research Institute | Approved |
| Apr 15, 2005 | HydroxyureaTreatment of pediatric patients with sickle cell anemia. | UPM Pharmaceuticals, Inc. | Designated |
| May 7, 1999 | Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda…Prevention of transient aplastic crisis in patients with sickle cell anemia. | MedImmune, Inc. | Designated |
| Dec 21, 1998 | Deferoxamine starch conjugateTreatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia. | Biomedical Frontiers, Inc. | Designated |
| Mar 25, 1992 | Polymeric oxygenTreatment of sickle cell anemia. | Capmed USA | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA